Raymond James analyst Dane Leone upgraded Relay Therapeutics to Strong Buy from Outperform with an unchanged price target of $29 following the RLY-2608 data presentation. The principal platform validation for the Dynamo drug discovery and development platform, increased PI3KH mutant specificity leading to differential toxicity, "was clearly achieved" with no high grade hyperglycemia, the analyst tells investors in a research note. The firm says the lack of discontinuation and limited reductions bode well for sustained dosing intensity, later responses, and durability of benefit.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RLAY:
- Relay Therapeutics to Participate in Two Upcoming Investor Conferences
- Relay Therapeutics upgraded to Strong Buy from Outperform at Raymond James
- Relay Therapeutics price target lowered to $15 from $23 at Barclays
- Relay Therapeutics Plunges on Latest Cancer Data
- Oppenheimer ‘not surprised’ by Relay plunge, but thinks 2608 ‘looks like a drug’